Related Experiment Video
Updated: Jun 18, 2026
04:15
A Flow Cytometry-Based High-Throughput Technique for Screening Integrin-Inhibitory Drugs
Published on: February 2, 2024
Small molecule integrin antagonists in cancer therapy
Mayra Paolillo1, Marika A Russo, Massimo Serra
1Dipartimento di Farmacologia Sperimentale ed Applicata, Università di Pavia, Italy. mayra.paolillo@unipv.it
Mini Reviews in Medicinal Chemistry
|November 26, 2009
Summary
Small molecule antagonists targeting integrins, like alphavbeta3 and alphavbeta5, show promise in blocking tumor growth and metastasis. Cilengitide is a key cyclic peptidic antagonist in clinical trials for cancer therapy.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Integrins are dimeric receptors mediating cell-ECM interactions, regulating crucial cellular processes.
- Integrin activation is implicated in pathological conditions, including tumor growth and metastasis.
- Understanding integrin structure is key to developing targeted therapies.
Purpose of the Study:
- To review small molecule antagonists targeting alphavbeta3 and alphavbeta5 integrins for cancer therapy.
- To highlight the therapeutic potential of blocking integrin-ECM interactions.
- To discuss the role of integrin antagonists in combination therapies.
Main Methods:
- Focus on small molecule antagonists, particularly for alphavbeta3 and alphavbeta5 integrins.
- Review of recent advances in crystallographic structures of integrins.
- Analysis of cilengitide as a cyclic peptidic antagonist in clinical trials.
Main Results:
- Small molecule antagonists can block integrin binding to ECM proteins.
- Inhibition of integrin biological effects can impede tumor growth and metastasis.
- Cilengitide demonstrates potential as an anti-cancer therapeutic.
Conclusions:
- Small molecule antagonists of alphavbeta3 and alphavbeta5 integrins are valuable tools for cancer therapy.
- Combination therapies involving integrin antagonists may offer enhanced strategies against cancer.
- Further research into integrin-targeted therapies holds significant promise for oncology.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:15Activation of Integrins
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
01:10Integrins
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM.
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
01:25Selectins
Cell adhesion is an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain, which...